Apyx Medical Corp. Hits New 52-Week High of $4.97, Up 198%

Apyx Medical Corp., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 4.97 on June 8, 2026. This achievement marks a remarkable 198.12% increase in the company's stock price over the past year, significantly outperforming the S&P 500, which has seen a gain of 23.42% during the same period. With a market capitalization of USD 152 million, Apyx Medical Corp. operates in a competitive industry where innovation and market positioning are crucial. The company's current financial metrics indicate a debt-to-equity ratio of 0.24, suggesting a manageable level of debt relative to equity. However, it is important to note that Apyx Medical is currently loss-making, reflected in its negative return on equity of -76.38%. The stock's previous 52-week low was recorded at USD 1.59, highlighting the substantial growth it has experienced in the past year. As Apyx Medical Corp. continues to navigate the dynamic landscape of pharmaceuticals and biotechnology, this new high underscores its evolving market presence.